EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Supermax Corporation Bhd (7106) fair value: what the stock is really worth

As of Oct 9, 2026: fair value of Supermax Corporation Bhd MYR 0.25, price MYR 0.44, upside -42.5%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · MY · ISIN MYL7106OO007

SC Thin data Oct 1, 2026

Supermax Corporation Bhd

7106 · KLSE

Weakest SetupStrongly overvalued and low quality.

Low debt
Quality 46/100
Mixed vs. peers (4/10)
Fair value 0.2500 MYR · Strongly overvalued (−42.5%)
Weak Growth (revenue 5y −36.5 %/yr in MYR)
Loss-making · -20.9% net margin (TTM)
Negative free cash flow
Narrow moat 22/100
Thin data

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.58 MYR 0.2500 MYR Fair Value 0.2500 MYR Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range 0.2500 MYR – 2.58 MYR · fair‑value band 0.1600 MYR – 0.3100 MYR · the 0.4350 MYR price screens above the 0.2500 MYR fair value. Dashed = 300-day average. As of Oct 1, 2026.

Follow Supermax Corporation Bhd in your weekly email

Every Wednesday you see whether Supermax Corporation Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Europe, North America, Central America, South America, Asia, Oceania, and Africa. It operates through four segments: Investment Holding, Manufacturing of Gloves, Trading of Gloves, and Others.

Show more

Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Europe, North America, Central America, South America, Asia, Oceania, and Africa. It operates through four segments: Investment Holding, Manufacturing of Gloves, Trading of Gloves, and Others. The company offers various types of nitrile latex and natural rubber gloves, as well as personal protective equipment. It is also involved in the trading, importing, and distribution of latex gloves; generation of biomass energy; marketing and distribution of healthcare products and medical devices; manufactures and sells face masks; and property holding activities. The company sells its products to laboratories, pharmacists, hospitals, doctors, and surgeons under the SUPERMAX, AURELIA, and MAXTER brands. It also exports its products to approximately 165 countries. The company was founded in 1987 and is headquartered in Sungai Buloh, Malaysia.

Stock analysis

Supermax Corporation Bhd (7106) currently trades at 0.4350 MYR, while our model-based Fair Value estimate is 0.2500 MYR, 42.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Scenario range: 0.1600 MYR (bear) to 0.3100 MYR (bull), the price of 0.4350 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Supermax Corporation Bhd reported revenue of 737M MYR in FY2025 versus 2.7B MYR in FY2021, a compound −27.6%/yr. Reported net income was −154M MYR in FY2025.

Key figures

Market cap 1.3B MYR (≈ $328M) · P/S ratio 1.66 · EPS (TTM) −0.0500 MYR · Net margin −20.9% · Return on equity −3.9% · Return on assets (EBIT) 0.0% · Operating margin 11.2% · Revenue (TTM) 737M MYR.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 74% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −36% fair-value upside, at −43%, 7106 screens richer than that median.

Fair Value models

Bear 0.1600 MYR Fair Value 0.2500 MYR Bull 0.3100 MYR
Price 0.4350 MYR · Upside -42.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.6300 MYR 0.8400 MYR 1.26 MYR 54
All 1 models by family
Asset-Based
NCAV (Graham) 0.6300 MYR 0.8400 MYR 1.26 MYR 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 46/100

Of which business quality 46 · Market factors (momentum, volatility) 54

Profitability 2
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 56
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 45
Distance to the 52-week high (market factor)
Net Issuance 82
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.5%
Start year 2020 (pandemic). Over 10 years: −3.5% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
70.2% (2020) → −29.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

7106 screens overvalued: fair value 43% below the price. Compare with Intuitive Surgical, Inc →

Compare Supermax Corporation Bhd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Bottom 25%
Fair Value upside −42.5% · Below median
Profitability
Return on assets −3.1% · Bottom 25%
Net margin (TTM) −20.9% · Bottom 25%
Operating margin (TTM) 11.2% · Below median
Growth and dividend
Revenue growth 42.5% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 0.09× · Cheapest 25%
P/S (TTM) 0.45× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 28
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $89.50 $134.36 +50% vs 7106
EssilorLuxottica Société anonyme EL €146.65 €161.32 +10% vs 7106
Intuitive Surgical, Inc ISRG $406.48 $348.72 −14% vs 7106
Medline Inc MDLN $35.55 $29.06 −18% vs 7106
Alcon Inc ALC $63.13 $40.13 −36% vs 7106
Becton, Dickinson and Company BDX $180.16 $104.73 −42% vs 7106
Straumann Holding STMN CHF 89.84 CHF 45.50 −49% vs 7106
West Pharmaceutical Services, Inc WST $364.98 $137.81 −62% vs 7106
Sartorius Stedim Biotech S.A DIM €212.80 €54.82 −74% vs 7106
Sartorius Aktiengesellschaft SRT €206.50 €42.05 −80% vs 7106

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Supermax Corporation Bhd Fair Value". https://www.fairvalue-calculator.com/stock/7106

Frequently asked questions

Is Supermax Corporation Bhd (7106) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of 0.2500 MYR versus a price of 0.4350 MYR, about −43% upside (overvalued).
What is the fair value of 7106?
Our model-based fair value for Supermax Corporation Bhd is 0.2500 MYR (as of Oct 1, 2026), built from audited fundamentals. The current price: 0.4350 MYR.
What is the quality score of 7106?
Supermax Corporation Bhd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Supermax Corporation Bhd (7106)?
Our model-based price target is the fair value of 0.2500 MYR (as of Oct 1, 2026) from 1 valuation models. Cautious scenario 0.1600 MYR, optimistic scenario 0.3100 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Supermax Corporation Bhd stock forecast for 2026?
Our models put fair value at 0.2500 MYR, about −43% upside versus a price of 0.4350 MYR (overvalued). Cautious scenario 0.1600 MYR, optimistic scenario 0.3100 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Supermax Corporation Bhd (7106)?
Supermax Corporation Bhd reported trailing-twelve-month revenue of about 737M MYR (latest available figure, as of Oct 1, 2026).
What is the intrinsic value of Supermax Corporation Bhd (7106)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Supermax Corporation Bhd it is 0.2500 MYR per share (as of Oct 1, 2026), against a price of 0.4350 MYR. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Supermax Corporation Bhd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 7106 trades above its calculated fair value: price 0.4350 MYR, fair value 0.2500 MYR, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7106?
No. The price is what the market pays today (0.4350 MYR); the fair value is what the company's own numbers justify (0.2500 MYR). For Supermax Corporation Bhd the two are 0.1850 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Supermax Corporation Bhd worth?
The market values Supermax Corporation Bhd at about 1.3B MYR (market capitalisation, as of Oct 1, 2026). Per share that is 0.4350 MYR; our models calculate a fair value of 0.2500 MYR per share.
What do the bullish and bearish scenarios say about 7106?
Our models span a range for Supermax Corporation Bhd: cautious scenario 0.1600 MYR, base 0.2500 MYR, optimistic 0.3100 MYR per share (as of Oct 1, 2026, price 0.4350 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Supermax Corporation Bhd (7106)?
Balance-sheet figures for Supermax Corporation Bhd (as of Oct 1, 2026): return on equity −3.9%, debt of 0.00 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 7106 from its 52-week high?
Supermax Corporation Bhd trades at 0.4350 MYR, about 16% below its 52-week high of 0.5200 MYR and 74% above the low of 0.2500 MYR (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 0.2500 MYR is for.
Which stocks are comparable to Supermax Corporation Bhd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Supermax Corporation Bhd stock attractive at the current price?
The data as of Oct 1, 2026: price 0.4350 MYR, calculated fair value 0.2500 MYR (−43%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7106 calculated?
We run Supermax Corporation Bhd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.2500 MYR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.6 % above its aggregate fair value. Supermax Corporation Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Supermax Corporation Bhd (7106)?
The closing price on Oct 9, 2026 was 0.4350 MYR. Our model-based fair value is 0.2500 MYR, about −43% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Supermax Corporation Bhd right now?
The price sits above even our optimistic bull case (0.3100 MYR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.1600 MYR to 0.3100 MYR) leaves room in how you read the outcome.

Key figures of Supermax Corporation Bhd

How large is the market capitalisation of Supermax Corporation Bhd (7106)?
The market capitalisation of Supermax Corporation Bhd is 1.3B MYR (≈ $328M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Supermax Corporation Bhd (7106)?
The price-to-sales ratio of Supermax Corporation Bhd is 1.66 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Supermax Corporation Bhd (7106)?
Earnings per share at Supermax Corporation Bhd are −0.0500 MYR. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Supermax Corporation Bhd (7106)?
The net margin of Supermax Corporation Bhd is −20.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Supermax Corporation Bhd (7106)?
The return on equity (ROE) of Supermax Corporation Bhd is −3.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Supermax Corporation Bhd (7106)?
On an EBIT basis the return on assets of Supermax Corporation Bhd is 0.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Supermax Corporation Bhd (7106)?
The operating margin of Supermax Corporation Bhd is 11.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Supermax Corporation Bhd (7106)?
Revenue at Supermax Corporation Bhd is growing +42.5% versus a year earlier (3y avg −3.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Supermax Corporation Bhd (7106)?
Earnings per share at Supermax Corporation Bhd are growing −92.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Supermax Corporation Bhd (7106) generate?
The free cash flow of Supermax Corporation Bhd is −252M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Supermax Corporation Bhd (7106) hold?
Supermax Corporation Bhd holds more cash than debt, 398M MYR net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Supermax Corporation Bhd in the live analysis

One click puts Supermax Corporation Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.